+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Steady state pharmacokinetics of nevirapine, didanosine, zalcitabine, and zidovudine combination therapy in HIV-1 positive patients



Steady state pharmacokinetics of nevirapine, didanosine, zalcitabine, and zidovudine combination therapy in HIV-1 positive patients



Pharmaceutical Research (New York) 12(9 Suppl. ): S101




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 033488959

Download citation: RISBibTeXText


Related references

Population pharmacokinetics of nevirapine, zidovudine and didanosine after combination therapy in HIV-infected patients. Clinical Pharmacology & Therapeutics 63(2): 182, 1998

Effect of RG 83894 on the steady-state pharmacokinetics of zidovudine and didanosine in HIV-positive patients. Pharmaceutical Research (New York) 11(10 Suppl. ): S430, 1994

Retrospective study of zidovudine or didanosine monotherapy or zalcitabine plus zidovudine combination therapy in patients with early AIDS. TENTH INTERNATIONAL CONFERENCE ON AIDS, INTERNATIONAL CONFERENCE ON STD [Author] Tenth International Conference on AIDS and the International Conference on STD, Vol 1; The global challenge of AIDS: Together for the future : 1) 209, 1994

Evolution of HIV drug resistance in zidovudine/zalcitabine- and zidovudine/didanosine-experienced patients receiving lamivudine-containing combination therapy. Antiviral Therapy 3(2): 81-88, 1998

Quality of life outcomes of combination zidovudine- didanosine-nevirapine and zidovudine-didanosine for antiretroviral-naive advanced HIV-infected patients. Aids 14(16): 2567-2574, 2000

In HIV-infected individuals who desire combination antiviral therapy, zidovudine plus zalcitabine is preferred to zidovudine plus didanosine. Reviews in Medical Virology 4(1): 5-8, 1994

In HIV-infected individuals who desire combination antiviral therapy, zidovudine plus didanosine is preferred to zidovudine plus zalcitabine. Reviews in Medical Virology 4(1): 9-12, 1994

Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Journal of Infectious Diseases 173(6): 1354-1366, 1996

A Comparative Study of a Combination of Zidovudine, Didanosine and Double Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine. AMERICAN SOCIETY FOR MICROBIOLOGY [Author] Human retroviruses and related infections : 125, 1995

Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team. Journal of Acquired Immune Deficiency Syndromes 22(3): 260-266, 1999

Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes 22(3): 260-266, 1999

Combination zidovudine and didanosine therapy for patients remaining persistently hiv p24 antigen positive despite zidovudine monotherapy. Viii International Conference on Aids And The Iii Std World Congress Viii International Conference on Aids And The Iii Std World Congress; Harvard-Amsterdam Conference, Amsterdam, Netherlands, July 19-24, Pagination Varies Viii International Conference on Aids And The Iii Std World Congress: Amsterdam, Netherlands Paper : b183, 1992

Modelling the use of triple combination therapy in five countries Nevirapine, zidovudine, and didanosine. Aids (london). 12(Suppl. 4): S59,., 1998

Modeling the use of triple combination therapy in five countries: nevirapine, Zidovudine, and Didanosine. Value in Health 3(3): 186-201, 2006

Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group. Aids 13(7): 851-858, 1999